Recently, studies have identified a core regulatory circuit (CRC) including half a dozen transcription factors that drive a subset of neuroblastomas with noradrenergic cell identity, including most MYCN-amplified cases15–18. The gene discussed is MYCN; the disease is neuroblastoma.